Immuneering Corporation - Class A (IMRX) earnings
IMRX earnings moved a median of -0.55% by the close. Quarterly and annual IMRX reports and results, each read against the price at its own news timestamp. Back to the IMRX overview →
22 measured IMRX earnings events.
Where these IMRX earnings landedvs 20 measured IMRX earnings reactions
| Middle 50% of IMRX earnings reactions | -4.20% to +4.30% |
|---|---|
| Median reaction (to close) | -0.55% |
| Measured reactions | 20 |
Point-in-time · zero look-ahead
Half of the 20 IMRX earnings events with a measured close landed between -4.20% and +4.30%; 50% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Immuneering Corp For: Jun 30 | SEC filing · Form 10-Q | -0.90% | -1.57% | |
| Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates | Press release | -0.90% | -1.57% | |
| Form 10-Q Immuneering Corp For: Mar 31 | SEC filing · Form 10-Q | +1.15% | +1.18% | |
| Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates | Press release | +1.15% | +1.18% | |
| Form 10-K Immuneering Corp For: Dec 31 | SEC filing · Form 10-K | +1.96% | +9.90% | |
| Form 10-Q Immuneering Corp For: Sep 30 | SEC filing · Form 10-Q | +1.61% | — | |
| Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates | Press release | +1.61% | — | |
| Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025 | Press release | -0.16% | +0.47% | |
| Form 10-Q Immuneering Corp For: Jun 30 | SEC filing · Form 10-Q | -1.89% | -4.40% | |
| Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates | Press release | -1.89% | -4.40% | |
| Form 10-Q Immuneering Corp For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -6.30% | |
| Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates | Press release | +0.00% | -6.30% | |
| Form 10-K Immuneering Corp For: Dec 31 | SEC filing · Form 10-K | +2.63% | +18.42% | |
| Form 10-Q Immuneering Corp For: Sep 30 | SEC filing · Form 10-Q | +10.30% | +4.30% | |
| Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates | Press release | +10.30% | +4.30% | |
| Form 10-Q Immuneering Corp For: Jun 30 | SEC filing · Form 10-Q | +5.38% | -4.20% | |
| Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates | Press release | +5.38% | -4.20% | |
| Form 10-Q Immuneering Corp For: Mar 31 | SEC filing · Form 10-Q | +4.45% | +5.16% | |
| Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates | Press release | +4.45% | +5.16% | |
| Form 10-K Immuneering Corp For: Dec 31 | SEC filing · Form 10-K | +0.00% | +1.15% | |
| Form 10-Q Immuneering Corp For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -2.72% | |
| Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates | Press release | +0.00% | -2.72% |
Keep exploring
More IMRX: analyst actions → · SEC filings → · IMRX overview →